Physician profile
Robert Oubre
NPI 1518386648
$1,395.78
in general payments reported to CMS, 2019-2025
18 companies · $120 in 2025
The $120 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $49.91 · 2021: $107 · 2022: $198 · 2023: $430 · 2024: $177 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $727.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $417.97 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $279.39 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $124.87 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $81.38 | 2019 | |
| Medtronic, INC. | $77.36 | 2025 | Protege Rx |
| Merck Sharp & Dohme LLC | $65.33 | 2022-2024 | Verquvo |
| Paratek Pharmaceuticals, INC. | $65.24 | 2023-2024 | Nuzyra |
| Astrazeneca Pharmaceuticals LP | $46.14 | 2019-2023 | Farxiga |
| Vifor Pharma, INC. | $40.44 | 2021 | |
| Mylan Specialty L.P. | $40.06 | 2023 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.72 | 2019-2020 | |
| Inari Medical, INC. | $22.58 | 2022 | |
| Glaxosmithkline, LLC. | $22.25 | 2023 | Trelegy Ellipta |
| Epizyme, INC. | $20.62 | 2021 | |
| Amgen INC. | $20.27 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eusa Pharma (US) LLC | $18.17 | 2019 | |
| Genentech USA, INC. | $15.69 | 2024 | Venclexta |
| Shire North American Group INC | $14.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Oubre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.